Log in to search using one of your social media accounts:

 

IL-23 Blocker for Psoriasis Successful in Extension Trials IL-23 Blocker for Psoriasis Successful in Extension Trials
For those with chronic plaque psoriasis, responses to tildrakizumab, an experimental interleukin-23 inhibitor, were upheld in two long-term extension studies, and FDA approval could be in the offing.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Dermatology News Source Type: news

New two-year tremfya ™ (guselkumab) data show patients with moderate to severe plaque psoriasis achieved consistent rates of skin clearance
More than 80 percent of patients receiving TREMFYA ™, including patients transitioned from Humira® to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100 (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 18, 2017 Category: Pharmaceuticals Source Type: news

Psoriasis Severity Tied to Greater Death Risk
(MedPage Today) -- Risk calculated based on Body Surface Area measurement (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 17, 2017 Category: Dermatology Source Type: news

Medical News Today: Best shampoo for psoriasis: What to look for
Psoriasis is a skin condition that also affects the scalp in an estimated 50 percent of cases. Learn more about its treatment with medicinal shampoos. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 17, 2017 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news

Janssen receives chmp positive opinion for guselkumab recommending approval for the treatment of moderate to severe plaque psoriasis in the european union
Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23 (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 16, 2017 Category: Pharmaceuticals Source Type: news

Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis
The drug selectively targets IL-23, a key driver of the immune inflammatory response in patients with psoriasis.International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23 FOR MEDICAL AND TRADE MEDIA ONLY BEERSE, Belgium, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen-Cilag International NV annou... Biopharmaceuticals, Dermatology, Regulatory Janssen-Cilag, Janssen, guselkumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 15, 2017 Category: Pharmaceuticals Source Type: news

European panel backs Janssen's psoriasis drug
(Reuters) - A European Medicines Agency (EMA) panel recommended the approval of Johnson& Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis' Cosentyx ® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland. (Source: World Pharma News)
Source: World Pharma News - September 15, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Hepatitis B and C Viruses and Biologics Hepatitis B and C Viruses and Biologics
How should one approach patients with HBV or HCV who are candidates for biological therapy for psoriasis or other skin disorders?Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Testing the Healing Potential of Light
From migraines to psoriasis to depression, researchers are looking at new ways to use light therapy. (Source: WebMD Health)
Source: WebMD Health - September 13, 2017 Category: Consumer Health News Source Type: news

Cochrane Skin Group celebrate 20 years of improving treatment of skin diseases
World-leading dermatologists and their patients are celebrating huge improvements in the treatment of skin diseases like skin cancer, psoriasis, and acne as theCochrane Skin Group marks its 20th anniversary this week.   The effects of the 120 plus published Cochrane Skin Reviews have been far-reaching and have had real impacts on patient care. These include skin cancer, skin allergies, and acne, blistering diseases, hair disorders like alopecia, fungal infections and psoriasis as well as tropical parasitic disea ses.The group is coordinated by the University of Nottingham ’s Centre of Evidence Based Dermatology ...
Source: Cochrane News and Events - September 12, 2017 Category: Information Technology Authors: Muriah Umoquit Source Type: news

A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia
We describe the purification from porcine colonic tissue extracts of an agonistic ligand for GPR15 and its functional characterization. In humans, this ligand, which we named GPR15L, is encoded by the gene C10ORF99 and has some features similar to the CC family of chemokines. GPR15L was found in some human and mouse epithelia exposed to the environment, such as the colon and skin. In humans, GPR15L was also abundant in the cervix. In skin, GPR15L was readily detected after immunologic challenge and in human disease, for example, in psoriatic lesions. Allotransplantation of skin from Gpr15l-deficient mice onto wild-type mic...
Source: Signal Transduction Knowledge Environment - September 12, 2017 Category: Science Authors: Suply, T., Hannedouche, S., Carte, N., Li, J., Grosshans, B., Schaefer, M., Raad, L., Beck, V., Vidal, S., Hiou-Feige, A., Beluch, N., Barbieri, S., Wirsching, J., Lageyre, N., Hillger, F., Debon, C., Dawson, J., Smith, P., Lannoy, V., Detheux, M., Bitsch Tags: STKE Research Articles Source Type: news

Scientific Reports: Fire ant venom could treat psoriasis
In trials on mice at the Emory University School of Medicine, Atlanta, the new cream was showed to reduce skin thickening and inflammation - both are typical features of the incurable disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2017 Category: Consumer Health News Source Type: news

Fire ant venom could treat psoriasis, scientists claim
In trials on mice at the Emory University School of Medicine, Atlanta, the new cream was showed to reduce skin thickening and inflammation - both are typical features of the incurable disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2017 Category: Consumer Health News Source Type: news

FDA details possible regulatory paths for Strata Sciences Optimal Dosing Tech
Strata Skin Sciences (NSDQ:SSKN) said this week it received a response letter from the FDA concerning possible 510(k) clearance paths for its Optimal Dosing Technology initially designed for treating psoriasis, vitiligo and other skin conditions. The Horsham, Penn.-based said the federal watchdog proposed 2 alternative paths, the 1st of which would require a clinical trial to substantiate its potential claims for the device and the 2nd would seek clearance “with no new claims regarding treatment or efficacy.” Strata said that should the company pursue the 2nd option, it would “likely consider initiat...
Source: Mass Device - September 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Strata Skin Sciences Source Type: news

Could Targeted Medical Information Help Develop Better Devices?
Do you know how your browsing information can be used? Nigel Syrotuck   Five years ago, The New York Times famously ran a piece explaining how Target sent maternity coupons to a customer that they (correctly) inferred was pregnant by examining her purchase history, before she had even told her family about it. More recently, Gizmodo ran a story about a person who was (incorrectly) targeted with a mailed letter inviting her to join a psoriasis clinical trial. Not only did she not have psoriasis, but the only relevance to her was that she had researched psoriasis and other skin ca...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nigel Syrotuck Tags: Design Source Type: news

Many Moisturizers Aren't What They Claim to Be
WEDNESDAY, Sept. 6, 2017 -- Many skin moisturizers that claim to be fragrance-free or hypoallergenic are not, and may aggravate skin disorders such as psoriasis and eczema, a new study says. Northwestern University researchers examined the top 100... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2017 Category: General Medicine Source Type: news

Severe Psoriasis Linked to Higher Risk of Earlier Death
Title: Severe Psoriasis Linked to Higher Risk of Earlier DeathCategory: Health NewsCreated: 9/5/2017 12:00:00 AMLast Editorial Review: 9/6/2017 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - September 6, 2017 Category: Dermatology Source Type: news

Severe Psoriasis Tied to Risk of Earlier Death
But experts say there may be ways to reduce those odds (Source: WebMD Health)
Source: WebMD Health - September 5, 2017 Category: Consumer Health News Source Type: news

Severe Psoriasis Linked to Higher Risk of Earlier Death
But experts say there may be ways to reduce those odds Source: HealthDay Related MedlinePlus Pages: Health Statistics, Psoriasis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 5, 2017 Category: Consumer Health News Source Type: news

Severe Psoriasis Linked to Higher Risk of Earlier Death
TUESDAY, Sept. 5, 2017 -- People with severe cases of the skin disease psoriasis appeared to have almost double the risk of dying during a four-year study than people without the condition, research suggests. But the increased death rate was only... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 5, 2017 Category: General Medicine Source Type: news

CME Outfitters Launches Two Free Activities on the Treatment & ...
CMEO launches two new free CMEO “Snacks” on new treatment strategies and best practices for managing moderate-to-severe psoriasis(PRWeb September 05, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14661655.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 5, 2017 Category: Pharmaceuticals Source Type: news

Does Biologic Risk Tolerance Vary?
(MedPage Today) -- Risk tolerance varies for pregnant patients with psoriasis (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 3, 2017 Category: American Health Source Type: news

Psoriasis: Metabolomics May Soon Improve Disease Management
(MedPage Today) -- Beyond genetics and immunology, a new frontier in research (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 1, 2017 Category: Dermatology Source Type: news

Psoriasis sufferers are TWICE as likely to die early
Researchers from the University of Pennsylvania found that patients whose disorder covers more than 10 percent of their body have nearly double the risk of passing away prematurely. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Death risk almost doubles with severe psoriasis, study suggests
Researchers have found that patients with psoriasis that affects more than 10 percent of their body surface area may have an increased risk of death. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news

Education, Screening for Psoriatic Arthritis Key in Psoriasis Education, Screening for Psoriatic Arthritis Key in Psoriasis
A new study compares screening methods for psoriatic arthritis, underscoring the importance of incorporating patient education and screening of PsA into clinical assessment of patients with psoriasis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Long-term Adherence to Topical Psoriasis Treatment Long-term Adherence to Topical Psoriasis Treatment
While psoriasis is a chronic disease requiring long-term treatment adherence, this study finds that many patients are falling short.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Psoriasis and suicidality: a systematic review and meta-analysis - Singh S, Taylor C, Kornmehl H, Armstrong AW.
BACKGROUND: Psoriasis is associated with psychiatric comorbidities; however, the relationship between psoriasis and suicidality is not well understood. OBJECTIVE: To perform a systematic review and meta-analysis that elucidates the relationship bet... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Maternal Stress and the Psoriasis Risk in Offspring Maternal Stress and the Psoriasis Risk in Offspring
Are children exposed to severe maternal stress in utero at greater risk of developing psoriasis later in life?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

NASH FibroSure Test Useful for Tracking Fibrosis in Psoriasis
(MedPage Today) -- Noninvasive test could lower number of liver biopsies needed (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 23, 2017 Category: Dermatology Source Type: news

Identifying Biomarkers in Psoriasis: A Metabolomics Approach Identifying Biomarkers in Psoriasis: A Metabolomics Approach
Using a systems metabolomics approach, a recent study identified an array of biomarkers that may be related to psoriasis pathogenesis and diagnosis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Arizona mother shares photo of psoriasis-suffering toddler
Charlie Nagy, 19 months old, from Arizona,  US, is one of youngest patients to have the condition so severe. People have accused parents Ashley and Andrew of allowing her to get sunburnt. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2017 Category: Consumer Health News Source Type: news

Cosentyx Highly Effective in Scalp Psoriasis Cosentyx Highly Effective in Scalp Psoriasis
Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 15, 2017 Category: Dermatology Tags: Dermatology News Source Type: news

Medical News Today: Do probiotics for eczema work?
Eczema is one of the most common skin conditions in the United States, and research into treatment is ongoing. Learn about using probiotics to treat eczema (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 15, 2017 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news

Secukinumab for Psoriasis and Psoriatic Arthritis Secukinumab for Psoriasis and Psoriatic Arthritis
This article reviews phase II and phase III clinical trials for secukinumab, an IL-17A inhibitor which presents a promising new treatment approach for refractory psoriasis and psoriatic arthritis.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

National Psoriasis Foundation honors two Penn dermatologists
(University of Pennsylvania School of Medicine) The National Psoriasis Foundation has announced the winners of its Medical Professional Research Awards. Joel M. Gelfand, MD MSCE, a professor of Dermatology and Epidemiology, received the 2017 Outstanding Scientific Achievement Award. The award for Outstanding New Investigator went to Junko Takeshita, MD, PhD, MSCE, an assistant professor of Dermatology and Epidemiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2017 Category: International Medicine & Public Health Source Type: news

Psoriasis and psychiatric illnesses: What are the links?
(Wiley) A new review examines the potential link between psoriasis and mental health conditions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 11, 2017 Category: International Medicine & Public Health Source Type: news

Eczema and psoriasis treatment: THIS therapy could reduce the need for creams and tablets
ECZEMA - a condition which causes the skin to become itchy, dry, and sore and psoriasis red, flaky skin, are often treated with steroid creams and tablets. (Source: Daily Express - Health)
Source: Daily Express - Health - August 6, 2017 Category: Consumer Health News Source Type: news

Psoriasis Treatment in Skin of Color
(MedPage Today) -- When it comes to treating psoriasis, skin color matters (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 2, 2017 Category: Primary Care Source Type: news

Revlimid drives Celgene profit beat; raises EPS forecast
(Reuters) - Celgene Corp rode its flagship multiple myeloma drug Revlimid and a rebound in sales of Otezla for psoriasis to a modestly higher-than-expected second-quarter profit and raised its full-year earnings forecast on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - July 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Dermatology Unit Is Rebranded Ortho Dermatologics LAVAL, Quebec, July 27, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the launch of SILIQ™ (brodalumab) Injection... Biopharmaceuticals, Dermatology, Product Launch Valeant Pharmaceuticals, SILIQ, brodalumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 27, 2017 Category: Pharmaceuticals Source Type: news

Tremfya (guselkumab) for the Treatment of Plaque Psoriasis
Tremfya ™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis. (Source: Drug Development Technology)
Source: Drug Development Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

New Therapies in the Spotlight at AAD Summer Meeting New Therapies in the Spotlight at AAD Summer Meeting
Agents that target interleukin-23 for atopic dermatitis and psoriasis will be among the hot topics presented at the upcoming American Academy of Dermatology (AAD) Summer Meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2017 Category: Consumer Health News Tags: Dermatology News Source Type: news

What Sharks Can Teach Us About Our Health What Sharks Can Teach Us About Our Health
While many people fear sharks, that hasn't stopped them from using shark cartilage in the hopes of curing their cancer, arthritis, psoriasis, and diabetes, among other health conditions.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Prescribing Barriers in Psoriasis
(MedPage Today) -- Expert explores drawbacks to psoriasis treatments (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 23, 2017 Category: Primary Care Source Type: news

EU Clears Brodalumab (Kyntheum) for Plaque Psoriasis EU Clears Brodalumab (Kyntheum) for Plaque Psoriasis
Brodalumab is for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.International Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 21, 2017 Category: Dermatology Tags: Dermatology News Alert Source Type: news

Menlo Therapeutics Raises $50M
venBio leads Series C Financing of oral once-daily Anti-Pruritus Therapy in development for Pruritus of Atopic Dermatitis, Psoriasis and Prurigo Nodularis, and for Refractory Chronic Cough MENLO PARK, Calif., July 18, 2017 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Menlo Therapeutics, Serlopitant, pruritus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 18, 2017 Category: Pharmaceuticals Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news